Gefitinib Sensitivity in Lung Cancer Cell Lines
Author Information
Author(s): Noro Rintaro, Gemma Akihiko, Kosaihira Seiji, Kokubo Yutaka, Chen Mingwei, Seike Masahiro, Kataoka Kiyoko, Matsuda Kuniko, Okano Tetsuya, Minegishi Yuji, Yoshimura Akinobu, Kudoh Shoji
Primary Institution: Nippon Medical School
Hypothesis
What factors contribute to gefitinib sensitivity in lung cancer cell lines?
Conclusion
Akt phosphorylation without ligand stimulation may be a key factor in gefitinib sensitivity, particularly in adenocarcinomas.
Supporting Evidence
- Eight out of nine sensitive cell lines showed Akt phosphorylation without ligand stimulation.
- The ratio of phospho-Akt to total Akt was higher in sensitive cells than in resistant cells.
- PC9, a highly sensitive cell line, had an EGFR gene mutation.
- Sensitive cells frequently expressed phospho-Akt and phospho-EGFR without ligand stimulation.
Takeaway
Some lung cancer cells can respond to a drug called gefitinib even without certain mutations, and this response is linked to a specific protein being active without needing a signal.
Methodology
The study analyzed 23 lung cancer cell lines for gefitinib sensitivity using the MTT cell proliferation assay and examined protein expression and phosphorylation.
Limitations
The study is limited to in vitro findings and may not fully translate to in vivo responses.
Participant Demographics
The study included 23 lung cancer cell lines, comprising adenocarcinoma, squamous-cell carcinoma, and small-cell carcinoma types.
Statistical Information
P-Value
0.0016
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website